Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function (Q36371688)

13 August 2017

1 reference

title

Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function (English)

1 reference

13 August 2017

C P M Hayward

1

1 reference

13 August 2017

P Harrison

2

1 reference

13 August 2017

M Cattaneo

3

1 reference

13 August 2017

T L Ortel

4

1 reference

13 August 2017

A K Rao

5

1 reference

13 August 2017

Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis

6

1 reference

13 August 2017

1 February 2006

1 reference

Journal of Thrombosis and Haemostasis

13 August 2017

1 reference

13 August 2017

4

1 reference

13 August 2017

2

1 reference

13 August 2017

312-319

1 reference

The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults

13 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Evaluation of primary hemostasis in neonates with a new in vitro platelet function analyzer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

GPVI levels in platelets: relationship to platelet function at high shear

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

The role of the platelet function analyser (PFA‐100TM) in the characterization of patients with von Willebrand's disease and its relationships with von Willebrand factor and the ABO blood group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Influence of ABO blood groups on primary hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Acquired von Willebrand syndrome in aortic stenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

The low-frequency allele of the platelet collagen signaling receptor glycoprotein VI is associated with reduced functional responses and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Hermansky-Pudlak syndrome: infrequent bleeding and first report of Turkish and Pakistani kindreds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Assessment of thrombocytopenic disorders using the Platelet Function Analyzer (PFA-100).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Clinical application of the PFA-100

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Meloxicam, 15 mg/day, spares platelet function in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Antiplatelet effect of aspirin in patients with cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Duration of increased bleeding tendency after cessation of aspirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Monitoring of clopidogrel action: comparison of methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Platelet function predicts myocardial damage in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Platelet function testing to assess effectiveness of platelet transfusion therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Impact of plasmapheresis on platelet hemostatic capacity in healthy voluntary blood donors detected by the platelet function analyzer PFA-100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

Ultrastructural analysis of the distribution of von Willebrand factor and fibrinogen in platelet aggregates formed in the PFA-100

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2006.01771.X

10.1111/J.1538-7836.2006.01771.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference